GMAB News and Press, Genmab A/S From 04/08/24

2024-04-08 15:15:00 ET Summary Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion. The deal is the fourth acquisition of a China-related innovative drugmaker by a foreign company in the last four months. The deal comes...

2024-04-07 06:30:00 ET Summary ProfoundBio, a Seattle ADC company with an R&D facility in Suzhou, will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. China Medical System in-licensed povorcitinib, an oral JAK1 inhibitor, from San Franciscoȁ...

2024-04-03 04:17:15 ET More on Genmab: Genmab: Recent Updates Support The Growth Narrative Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade) Genmab announces ~$510M worth of share buybacks AbbVie/ Genmab win FDA priority review for lympho...

2024-04-02 01:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-23 00:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-15 09:26:51 ET More on Genmab Genmab: Recent Updates Support The Growth Narrative Genmab A/S (GMAB) Q4 2023 Earnings Call Transcript Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade) AbbVie/ Genmab win FDA priority review for lymp...

FDA grants Priority Review with target action date of June 28, 2024 Application based on results from Phase 1/2 EPCORE™ NHL-1 trial demonstrating clinically meaningful treatment responses in difficult-to-treat patients with relapsed or refractory (R/R) follicular lymphoma (FL) ...

2024-02-23 14:08:15 ET More on Genmab Genmab: Recent Updates Support The Growth Narrative Genmab A/S (GMAB) Q4 2023 Earnings Call Transcript Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade) Genmab reports FY results Genmab FY 202...

2024-02-21 03:44:55 ET Summary Genmab's 2023 annual report shows strong financial performance and continued clinical success, setting the company up for growth in 2024. The company's pipeline includes promising candidates and collaborations with industry giants, supporting future ...

2024-02-20 17:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...